Ben Stevens

Use of cannabis across the globe has grown by 40% over the last decade, with 256m people now reported to have used cannabis over the past year in 2024.

For more than a decade now, the world's largest retail conglomerates have been quietly building their consumer data empires. Today, their consumers' data is perhaps more valuable to these brands than the goods they want to sell them.

Curaleaf Holdings (CURA) announced this week that it intends to launch an unsolicited take-over bid of its rival Aurora Cannabis (ACB) in what would mark one of the most consequential consolidation moves in industry history.

More than a year has passed since the Advisory Council on the Misuse of Drugs (ACMD) was commissioned to conduct a formal review of the UK's medical cannabis industry.

Employers do not need a bespoke cannabis policy, their existing medicines, disability and occupational health processes should be applied.

The imminent launch of the first new European cannabis-based pharmaceutical for over five years could not have been better timed, it seems.

CANOPY Growth is primed to cull a host of existing brands as it looks to build a multi-market, seed-to-patient model and distance itself from a ‘false starts' legacy, says CEO Luc Mongeau.

James Duckenfield, CEO of Glass Pharms ® , explains the company's post-harvest process, including drying and curing, and why freeze-drying is never part of it

Whilst expressing empathy with patients impacted by the recent German crackdown on cannabis flower, the head of the country's leading wholesaler is bullish about its prospects – with orders up 50% since its purchase by Canadian cannabis giant High Tide.

Earlier this month, we published new data from two separate Freedom of Information (FOI) requests providing the most complete and up-to-date picture yet of the UK's medical cannabis market.